{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:21:00Z","timestamp":1778494860797,"version":"3.51.4"},"reference-count":92,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CF Foundation","award":["BASS22Q0-CI"],"award-info":[{"award-number":["BASS22Q0-CI"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>There is a well-established association between cystic fibrosis (CF) and malnutrition. Several comorbid conditions have also been associated with undernutrition in people with cystic fibrosis (PwCF). Highly effective modulator therapy has allowed for a paradigm shift altering disease progression and management. Modulator use has even been associated with acceleration of weight trajectory causing overnutrition, which can lead to cardiovascular and metabolic comorbid conditions. This review explores how nutritional status is evolving in the era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators in people with CF, specifically in children. By synthesizing current research, we aim to support pediatric healthcare providers and nutritionists in delivering tailored, proactive nutritional care in this new therapeutic landscape.<\/jats:p>","DOI":"10.3390\/nu17152533","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T08:51:41Z","timestamp":1754038301000},"page":"2533","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The State of Weight in Cystic Fibrosis: Understanding Nutritional Status and Individualizing Nutritional Care in the Modulator Era"],"prefix":"10.3390","volume":"17","author":[{"given":"Sapna","family":"Khemka","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology & Nutrition, Department of Pediatrics, Nationwide Children\u2019s Hospital, The Ohio State University, Columbus, OH 43205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie","family":"Hunter","sequence":"additional","affiliation":[{"name":"Children\u2019s Health Children\u2019s Medical Center, Dallas, TX 75235, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Jones","sequence":"additional","affiliation":[{"name":"Children\u2019s Health Children\u2019s Medical Center, Dallas, TX 75235, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishla","family":"Valent\u00edn-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Texas Southwestern, Dallas, TX 75390, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4981-9749","authenticated-orcid":false,"given":"Christina B.","family":"Chadwick","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosara","family":"Bass","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology & Nutrition, Department of Pediatrics, Nationwide Children\u2019s Hospital, The Ohio State University, Columbus, OH 43205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: A clinical and pathologic study","volume":"56","author":"Andersen","year":"1938","journal-title":"Am. J. Dis. Child."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bass, R., Brownell, J.N., and Stallings, V.A. (2021). The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status. Nutrients, 13.","DOI":"10.3390\/nu13092907"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: Prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J. Clin. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_6","first-page":"1521","article-title":"Effect of exocrine pancreatic function on resting energy expenditure in cystic fibrosis","volume":"96","author":"Moudiou","year":"2007","journal-title":"Acta Paediatr. Oslo Nor. 1992"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jcf.2023.02.008","article-title":"Early life growth trajectories in cystic fibrosis are associated with lung function at age six","volume":"22","author":"Psoter","year":"2023","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"Long term clinical effectiveness of ivacaftor in people with the G551DCFTRmutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF","volume":"22","author":"Proud","year":"2023","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: A CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in Cystic Fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0039-1696726","article-title":"Growth and Nutrition in Cystic Fibrosis","volume":"40","author":"Brownell","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_14","first-page":"100280","article-title":"Eating disorders and body image in cystic fibrosis","volume":"26","author":"Darukhanavala","year":"2021","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_15","first-page":"382","article-title":"Stunting is an independent predictor of mortality in patients with cystic fibrosis","volume":"32","author":"Vieni","year":"2013","journal-title":"Clin. Nutr. Edinb. Scotl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpeds.2013.02.026","article-title":"Pubertal height velocity and associations with prepubertal and adult heights in cystic fibrosis","volume":"163","author":"Zhang","year":"2013","journal-title":"J. Pediatr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamapediatrics.2017.0206","article-title":"Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life","volume":"171","author":"Leung","year":"2017","journal-title":"JAMA Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Marks, M.P., Heltshe, S.L., Baines, A., Ramsey, B.W., Hoffman, L.R., and Stalvey, M.S. (2021). Most Short Children with Cystic Fibrosis Do Not Catch Up by Adulthood. Nutrients, 13.","DOI":"10.3390\/nu13124414"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Anton-P\u0103duraru, D.-T., Murgu, A.M., Bozomitu, L.I., M\u00eendru, D.E., Iliescu Hali\u021bchi, C.O., Trofin, F., Ciongradi, C.I., S\u00e2rbu, I., E\u1e63anu, I.M., and Azoic\u0103i, A.N. (2024). Diagnosis and Management of Gastrointestinal Manifestations in Children with Cystic Fibrosis. Diagnostics, 14.","DOI":"10.3390\/diagnostics14020228"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s00431-021-04011-4","article-title":"Does cystic fibrosis make susceptible to celiac disease?","volume":"180","author":"Emiralioglu","year":"2021","journal-title":"Eur. J. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e100101","DOI":"10.15252\/embj.2018100101","article-title":"A pathogenic role for cystic fibrosis transmembrane conductance regulator in celiac disease","volume":"38","author":"Villella","year":"2019","journal-title":"EMBO J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002736","article-title":"Celiac Disease in Patients With Cystic Fibrosis on Ivacaftor: A Case Series","volume":"71","author":"Hjelm","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"C\u00e1rdenas-Torres, F.I., Cabrera-Ch\u00e1vez, F., Figueroa-Salcido, O.G., and Ontiveros, N. (2021). Non-Celiac Gluten Sensitivity: An Update. Med. Kaunas Lith., 57.","DOI":"10.3390\/medicina57060526"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcf.2012.09.002","article-title":"Eosinophilic esophagitis in cystic fibrosis: A case series and review of the literature","volume":"12","author":"Goralski","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.anai.2018.08.022","article-title":"Comparison of comorbid diagnoses in children with and without eosinophilic esophagitis in a large population","volume":"121","author":"Capucilli","year":"2018","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5223\/pghn.2022.25.4.283","article-title":"Epidemiology of Eosinophilic Esophagitis in Patients with Cystic Fibrosis: A Population-Based 5-Year Study","volume":"25","author":"Alaber","year":"2022","journal-title":"Pediatr. Gastroenterol. Hepatol. Nutr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/1744666X.2022.2096591","article-title":"Current treatment options and long-term outcomes in patients with eosinophilic esophagitis","volume":"18","author":"Lucendo","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1038\/ctg.2015.9","article-title":"Topical Steroid Therapy for the Treatment of Eosinophilic Esophagitis (EoE): A Systematic Review and Meta-Analysis","volume":"6","author":"Chuang","year":"2015","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cheng, K., Ashby, D., and Smyth, R.L. (2011). Oral steroids for long-term use in cystic fibrosis. Cochrane Database Syst. Rev., CD000407.","DOI":"10.1002\/14651858.CD000407.pub2"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S1569-1993(24)00601-5","article-title":"P303 Prevalence and clinical presentation of inflammatory bowel disease (IBD) in a large adult cystic fibrosis (CF) Unit","volume":"23","author":"Abel","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yu, M., Zhang, Q., Yuan, K., Sazonovs, A., Stevens, C., Fachal, L., The International Inflammatory Bowel Disease Genetics Consortium, Anderson, C.A., Daly, M.J., and Huang, H. (medRxiv, 2024). Cystic fibrosis risk variants confer protection against inflammatory bowel disease, medRxiv.","DOI":"10.1101\/2024.12.02.24318364"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clnu.2024.09.036","article-title":"The impact of a whole foods dietary intervention on gastrointestinal symptoms, inflammation, and fecal microbiota in pediatric patients with cystic fibrosis: A pilot study","volume":"43","author":"Green","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_33","unstructured":"(2023). Patient Registry Annual Data Report, Cystic Fibrosis Foundation."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2019.08.011","article-title":"Cystic fibrosis related diabetes: Nutrition and growth considerations","volume":"18","author":"Kaminski","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Drzyma\u0142a-Czy\u017c, S., Krzy\u017canowska, P., Koletzko, B., Nowak, J., Mi\u015bkiewicz-Chotnicka, A., Moczko, J., Lisowska, A., and Walkowiak, J. (2017). Determinants of Serum Glycerophospholipid Fatty Acids in Cystic Fibrosis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010185"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1515\/CCLM.2010.336","article-title":"Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease","volume":"48","author":"Robberecht","year":"2010","journal-title":"CCLM"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1203\/PDR.0b013e3181b4e8d3","article-title":"Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy","volume":"66","author":"Prieto","year":"2009","journal-title":"Pediatr. Res."},{"key":"ref_40","unstructured":"(2021). Patient Registry Annual Data Report, Cystic Fibrosis Foundation."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Salvatore, D., Padoan, R., Amato, A., Salvatore, M., Campagna, G., and On Behalf of the Italian Cf Registry Working Group (2024). Nutritional Trends in Cystic Fibrosis: Insights from the Italian Cystic Fibrosis Patient Registry. J. Clin. Med., 13.","DOI":"10.20944\/preprints202404.0869.v1"},{"key":"ref_42","unstructured":"(2025, July 21). Childhood Obesity Facts, Available online: https:\/\/www.cdc.gov\/obesity\/childhood-obesity-facts\/childhood-obesity-facts.html."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sheikh, S., Zemel, B.S., Stallings, V.A., Rubenstein, R.C., and Kelly, A. (2014). Body composition and pulmonary function in cystic fibrosis. Front. Pediatr., 2.","DOI":"10.3389\/fped.2014.00033"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1203\/00006450-199404000-00013","article-title":"Energy Expenditure and Genotype of Children with Cystic Fibrosis","volume":"35","author":"Tomezsko","year":"1994","journal-title":"Pediatr. Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Frantzen, T., Barsky, S., LaVecchia, G., Marowitz, M., and Wang, J. (2023). Evolving Nutritional Needs in Cystic Fibrosis. Life Basel Switz., 13.","DOI":"10.3390\/life13071431"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Freswick, P.N., Reid, E.K., and Mascarenhas, M.R. (2022). Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis. Nutrients, 14.","DOI":"10.3390\/nu14071341"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/apa.1989.78.s363.41","article-title":"The pathophysiology of the pancreatic defect in cystic fibrosis","volume":"363","author":"Durie","year":"1989","journal-title":"Acta Paediatr. Scand. Suppl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.3748\/wjg.v20.i33.11467","article-title":"Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21st century","volume":"20","author":"Trang","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor","volume":"55","author":"Munce","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_51","first-page":"99","article-title":"Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor","volume":"35","author":"Nichols","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): A phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2036.1991.tb00040.x","article-title":"Fate of orally ingested enzymes in pancreatic insufficiency: Comparison of two pancreatic enzyme preparations","volume":"5","author":"Delchier","year":"1991","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1021\/bi802280b","article-title":"Interfacial mechanism of phospholipase A2: pH-dependent inhibition and Me-beta-cyclodextrin activation","volume":"48","author":"Wacklin","year":"2009","journal-title":"Biochemistry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005176-198811001-00002","article-title":"Digestive and Absorptive Phase Anomalies Associated with the Exocrine Pancreatic Insufficiency of Cystic Fibrosis","volume":"7","author":"Roy","year":"1988","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1002\/ppul.26913","article-title":"The gastrointestinal microbiome, small bowel bacterial overgrowth, and microbiome modulators in cystic fibrosis","volume":"59","author":"Green","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jcf.2018.08.009","article-title":"Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis","volume":"18","author":"Bodewes","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/17474124.2014.851599","article-title":"Advances in understanding of bile acid diarrhea","volume":"8","author":"Camilleri","year":"2014","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"398585","DOI":"10.1155\/2015\/398585","article-title":"The interplay of the gut microbiome, bile acids, and volatile organic compounds","volume":"2015","author":"Sagar","year":"2015","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00394-020-02358-2","article-title":"Choline in cystic fibrosis: Relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota","volume":"60","author":"Bernhard","year":"2021","journal-title":"Eur. J. Nutr."},{"key":"ref_63","first-page":"878","article-title":"Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis","volume":"43","author":"Schnell","year":"2023","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"L542","DOI":"10.1152\/ajplung.00180.2010","article-title":"A new role for bicarbonate in mucus formation","volume":"299","author":"Chen","year":"2010","journal-title":"Am. J. Physiol.-Lung Cell Mol. Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1870402","DOI":"10.1080\/19490976.2020.1870402","article-title":"Association between antibiotics and gut microbiome dysbiosis in children: Systematic review and meta-analysis","volume":"13","author":"McDonnell","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"948367","DOI":"10.1155\/2012\/948367","article-title":"Update of Faecal Markers of Inflammation in Children with Cystic Fibrosis","volume":"2012","author":"Lee","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2036.2004.02174.x","article-title":"Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration","volume":"20","author":"Bruzzese","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Hevilla, F., Porras, N., Gir\u00f3n, M.V., Garc\u00eda-Olivares, M., Padial, M., S\u00e1nchez-Torralvo, F.J., Olveira, C., and Olveira, G. (2024). Impact of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study. Nutrients, 16.","DOI":"10.3390\/nu16193293"},{"key":"ref_69","first-page":"753","article-title":"Fat-free mass depletion in cystic fibrosis: Associated with lung disease severity but poorly detected by body mass index","volume":"26","author":"King","year":"2010","journal-title":"Nutr. Burbank Los Angel. Cty. Calif"},{"key":"ref_70","first-page":"715","article-title":"Association Between Fat-Free Mass and Pulmonary Function in Patients With Cystic Fibrosis: A Narrative Review","volume":"34","author":"Gomes","year":"2019","journal-title":"Nutr. Clin. Pract. Off. Publ. Am. Soc. Parenter. Enter. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","article-title":"Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity","volume":"32","author":"Alvarez","year":"2016","journal-title":"Nutrition"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Mouzaki, M., Dupuis, A., Avolio, J., Griffin, K., Ratjen, F., Tullis, E., and Gonska, T. (2023). Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1157459"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Merino S\u00e1nchez-Ca\u00f1ete, A., L\u00f3pez C\u00e1rdenes, C.M., Vicente Santamar\u00eda, S., Guti\u00e9rrez Mart\u00ednez, J.R., Su\u00e1rez Gonz\u00e1lez, M., \u00c1lvarez Merino, M., and Gonz\u00e1lez Jim\u00e9nez, D. (2024). Increased fat mass and obesity risk after elexacaftor-tezacaftor-ivacaftor therapy in young adults with cystic fibrosis. Front. Nutr., 11.","DOI":"10.3389\/fnut.2024.1477674"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"111124","DOI":"10.1016\/j.nut.2020.111124","article-title":"Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension","volume":"85","author":"King","year":"2021","journal-title":"Nutrition"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/ppul.27272","article-title":"Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis","volume":"59","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Westh\u00f6lter, D., Haubold, J., Welsner, M., Salh\u00f6fer, L., Wienker, J., Sutharsan, S., Stra\u00dfburg, S., Taube, C., Umutlu, L., and Schaarschmidt, B.M. (2024). Elexacaftor\/tezacaftor\/ivacaftor influences body composition in adults with cystic fibrosis: A fully automated CT-based analysis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-59622-2"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2300174","DOI":"10.1183\/13993003.00174-2023","article-title":"Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: A multinational retrospective cohort study","volume":"62","author":"Frost","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2009.09.002","article-title":"Prevalence of dyslipidemia in adults with cystic fibrosis","volume":"9","author":"Rhodes","year":"2010","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_80","first-page":"100308","article-title":"Coronary artery disease in patients with cystic fibrosis\u2014A case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_81","first-page":"100391","article-title":"Cholesterol and triglyceride concentrations following 12\u201318 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor-PROMISE sub-study","volume":"40","author":"Bass","year":"2025","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17534666251317200","DOI":"10.1177\/17534666251317200","article-title":"New era, new GOALs: Cardiovascular screening and lipid management in cystic fibrosis","volume":"19","author":"Despotes","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jcf.2024.08.007","article-title":"Cystic fibrosis foundation position paper: Redefining the CF care model","volume":"23","author":"Goetz","year":"2024","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1590\/1984-0462\/;2019;37;4;00007","article-title":"Prevalence of hepatic steatosis among children and adolescents with cystic fibrosis and its association with nutritional status","volume":"37","author":"Gobato","year":"2019","journal-title":"Rev. Paul. Pediatr."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Bernhard, W., Lange, R., Graepler-Mainka, U., Engel, C., Machann, J., Hund, V., Shunova, A., Hector, A., and Riethm\u00fcller, J. (2019). Choline Supplementation in Cystic Fibrosis-The Metabolic and Clinical Impact. Nutrients, 11.","DOI":"10.3390\/nu11030656"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"The InterAct Consortium (2013). The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: The EPIC-InterAct study. Diabetologia, 56, 60\u201369.","DOI":"10.1007\/s00125-012-2715-x"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jand.2020.03.015","article-title":"Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-Based Nutrition Practice Guideline","volume":"121","author":"McDonald","year":"2021","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcf.2024.08.005","article-title":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","volume":"24","author":"Park","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_90","first-page":"100375","article-title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review","volume":"38","author":"Ahmed","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3945\/an.112.003608","article-title":"Chronic Illness and Disordered Eating: A Discussion of the Literature","volume":"4","author":"Quick","year":"2013","journal-title":"Adv. Nutr."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Patel, D., Shan, A., Mathews, S., and Sathe, M. (2022). Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management. Nutrients, 14.","DOI":"10.3390\/nu14051028"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/15\/2533\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:20:21Z","timestamp":1760034021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/15\/2533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":92,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["nu17152533"],"URL":"https:\/\/doi.org\/10.3390\/nu17152533","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]}}}